Frazier Life Sciences Management’s Oric Pharmaceuticals ORIC Stock Holding History

Frazier Life Sciences Management’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,065,334	Closed	-$10.8M	–	52
2025 Q2	$10.8M	Sell	1,065,334 -344,859	-24%	-$2.32M	0.43%	38
2025 Q1	$7.87M	Sell	1,410,193 -2,478,045	-64%	-$21.7M	0.36%	33
2024 Q4	$31.4M	Sell	3,888,238 -254,617	-6%	-$2.34M	1.3%	20
2024 Q3	$42.5M	Hold	4,142,855	–	–	1.7%	20
2024 Q2	$29.3M	Hold	4,142,855	–	–	1.37%	22
2024 Q1	$57M	Buy	4,142,855 +2,000,000	+93%	+$23.8M	2.4%	13
2023 Q4	$19.7M	Hold	2,142,855	–	–	1.05%	26
2023 Q3	$13M	Hold	2,142,855	–	–	0.86%	30
2023 Q2	$16.6M	Buy	+2,142,855	New	+$12.2M	0.99%	27

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Frazier Life Sciences Management's ORIC Position: Q3 2025 in Review

Frazier Life Sciences Management sold out of Oric Pharmaceuticals (ORIC) in Q3 2025, closing a stake of 1,065,334 shares — an estimated $10.8M sold.

Frazier Life Sciences Management first reported a position in ORIC in Q2 2023 and held it in 9 quarters. The position peaked at $57M in Q1 2024. 152 funds tracked by Wall St. Rank hold ORIC as of Q3 2025.

Frazier Life Sciences Management reported no remaining Oric Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Frazier Life Sciences Management sold 1,065,334 Oric Pharmaceuticals shares in Q3 2025, an estimated $10.8M.
Frazier Life Sciences Management first reported a position in Oric Pharmaceuticals in Q2 2023 and held it in 9 quarters.
Frazier Life Sciences Management's Oric Pharmaceuticals position peaked at $57M in Q1 2024.
152 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2025.

Based on Frazier Life Sciences Management's 13F filing for Q3 2025, filed 14 Nov 2025.